CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 5,000 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Treated with CAR-T from July 1, 2018 under temporary authorization or covered by French health insurance
  • ✓Eligible for CAR-T treatment for hematological malignancy covered by French health insurance or in clinical trial
  • ✓CAR-T indication validated by multidisciplinary tumor board of qualified center
  • ✓Deemed eligible for CAR-T treatment after medical exam in qualified center
Key exclusion· 1
  • ✕Not registered with social security in France

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04328298
NCT04328298N/ARecruitingOn TrackUpdated 3mo ago
Long Recruiting
CompareCT.gov

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

The Lymphoma Academic Research Organisation·observational·Posted Mar 31, 2020·Updated Mar 4, 2026

In Brief

An observational study for Hematopathology Eligible or CAR-t Cell Treatment. Currently recruiting, targeting 5,000 participants across 36 sites.

Detailed Summary

This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHematopathology Eligible or CAR-t Cell Treatment
CountriesFrance
CollaboratorsGilead Sciences, Novartis, Bristol-Myers Squibb

Timeline

N/ARecruiting
20202021202220232024202520262027202820292030203120322033203420352036203720382039
First PostedMar 31, 2020
Enrollment StartDec 19, 2019
Primary CompletionDec 19, 2038
TodayJul 2, 2026
Enrollment to primary: 19 yearsPosted 6.3 years agoPrimary completion in 12.5 years